Ventas: Tough Road Ahead To A Growth Trajectory

Jun. 01, 2022 11:27 AM ETVentas, Inc. (VTR)CTRE, HR, LTC, SBRA, SHOP, WELL, SHOP:CA9 Comments


  • Ventas has delivered consistently poor price performance coupled with low dividends over the past ten years.
  • Ventas’ proposed “Pivot of Growth” was undermined by underperforming assets and sale of Life Sciences development.
  • Ventas has yet to realize the full potential of its acquisition.
  • Looking for more investing ideas like this one? Get them exclusively at The Total Pharma Tracker. Learn More »

Cryptocurrency investor trading at home using his laptop

hobo_018/E+ via Getty Images

Ventas, Inc. (NYSE:VTR) is one of the four major real estate investment trusts ((REITs)) which derives most of their earnings from senior housing operated portfolio (SHOP), owning or managing (through unconsolidated joint ventures) approximately


Performance (Seeking Alpha)

Pivot to growth

Pivot to growth (Ventas website)

About the TPT service

Thanks for reading. At the Total Pharma Tracker, we offer the following:-

Our Android app and website features a set of tools for DIY investors, including a work-in-progress software where you can enter any ticker and get extensive curated research material. 

For investors requiring hands-on support, our in-house experts go through our tools and find the best investible stocks, complete with buy/sell strategies and alerts.

Sign up now for our free trial, request access to our tools, and find out, at no cost to you, what we can do for you. 

This article was written by

Avisol Capital Partners profile picture
Cautious, low key, disciplined investing in biopharma stocks
Avisol Capital Partners runs the Total Pharma Tracker Seeking Alpha Marketplace service. This is managed by Dr Asok Dutta, BVScAH and Dr Udaya Kumar Maiya, MD Oncologist. The service offers end-to-end research on both investing and trading ideas everyday, and includes a 150-stock watchlist and two 40-stock model portfolios that are continuously tracked.

Dr Dutta is a retired veterinary surgeon. He has over 40 years experience in the industry. Dr Maiya is a well-known oncologist who has 30 years in the medical field, including as Medical Director of various healthcare institutions. Both doctors are also avid private investors. They are assisted by a number of finance professionals in developing this service.

If you want to check out our service, go here -

Disclaimer - we are not investment advisors.

Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Recommended For You

Comments (9)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.